Adamas Pharmaceuticals, Inc.

200 articles about Adamas Pharmaceuticals, Inc.

• Adamas Reports First Quarter 2021 Financial Results

  5/10/2021

  Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, reported financial results for the first quarter ended March 31, 2021, and recent corporate highlights.

• Adamas Announces New Employment Inducement Grant - May 07, 2021

  5/7/2021

  Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted five new employees restricted stock units to acquire 58,500 shares of the company’s common stock.

• Adamas to Present at Upcoming BofA Conference

  4/29/2021

  Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021.

• Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners

  4/27/2021

  Results of a survey co-sponsored by PMD Alliance and Adamas showed the need for education in the Parkinson’s community about OFF time and dyskinesia

• Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021

  4/26/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

• Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting

  4/15/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting

• Adamas to Present at Upcoming Needham Conference

  4/7/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12 – 15, 2021.

• Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease

  3/29/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled “Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson’s disease” in the peer-reviewed journal Frontiers in Neurology

• Adamas Announces New Employment Inducement Grant - Mar 05, 2021

  3/5/2021

  Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock.

• Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  3/1/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 shares of its common stock,

• Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering

  2/25/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share

• Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering

  2/24/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas.

• Adamas Reports Fourth Quarter and Full Year 2020 Financial Results

  2/23/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights.

• Adamas to Present at Upcoming Healthcare Conferences

  2/17/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences: 10 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 1:40 p.m. ET

• Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021

  2/10/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close

• Adamas Announces Settlement of Patent Litigation with Zydus

  2/1/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and Drug Administration to market a generic version of GOCOVR

• Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

  2/1/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine)

• 

  FDA Action Alert: Adamas, Mallinckrodt and Merck

  2/1/2021

  February is kicking off with a number of PDUFA dates for the U.S. FDA as well as a cancer advisory committee meeting. Here’s a look.

• Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021

  1/13/2021

  Total prescriptions of GOCOVRI of approximately 8,165 for fourth quarter 2020 and approximately 31,070* for full year 2020

• Adamas to Present at Upcoming ICR Conference

  1/7/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021. The fireside chat will be webcast live on January 14, 2021 at 11:30 a.m. Eastern Time on the inves